These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
317 related articles for article (PubMed ID: 22237663)
1. Impact of comorbidity on colorectal cancer screening cost-effectiveness study in diabetic populations. Dinh TA; Alperin P; Walter LC; Smith R J Gen Intern Med; 2012 Jun; 27(6):730-8. PubMed ID: 22237663 [TBL] [Abstract][Full Text] [Related]
2. Health benefits and cost-effectiveness of a hybrid screening strategy for colorectal cancer. Dinh T; Ladabaum U; Alperin P; Caldwell C; Smith R; Levin TR Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1158-66. PubMed ID: 23542330 [TBL] [Abstract][Full Text] [Related]
3. Contrasting Effectiveness and Cost-Effectiveness of Colorectal Cancer Screening Under Commercial Insurance vs. Medicare. Ladabaum U; Mannalithara A; Brill JV; Levin Z; Bundorf KM Am J Gastroenterol; 2018 Dec; 113(12):1836-1847. PubMed ID: 29904156 [TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of Screening Colonoscopy in Iranian High Risk Population. Javadinasab H; Daroudi R; Salimzadeh H; Delavari A; Vezvaie P; Malekzadeh R Arch Iran Med; 2017 Sep; 20(9):564-571. PubMed ID: 29048918 [TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness and budget impact analyses of colorectal cancer screenings in a low- and middle-income country: example from Thailand. Phisalprapa P; Supakankunti S; Chaiyakunapruk N J Med Econ; 2019 Dec; 22(12):1351-1361. PubMed ID: 31560247 [No Abstract] [Full Text] [Related]
6. Personalizing colonoscopy screening for elderly individuals based on screening history, cancer risk, and comorbidity status could increase cost effectiveness. van Hees F; Saini SD; Lansdorp-Vogelaar I; Vijan S; Meester RG; de Koning HJ; Zauber AG; van Ballegooijen M Gastroenterology; 2015 Nov; 149(6):1425-37. PubMed ID: 26253304 [TBL] [Abstract][Full Text] [Related]
7. High-Intensity Versus Low-Intensity Surveillance for Patients With Colorectal Adenomas: A Cost-Effectiveness Analysis. Meester RGS; Lansdorp-Vogelaar I; Winawer SJ; Zauber AG; Knudsen AB; Ladabaum U Ann Intern Med; 2019 Nov; 171(9):612-622. PubMed ID: 31546257 [TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness and cost-effectiveness of screening colonoscopy vs. sigmoidoscopy and alternative strategies. Sharaf RN; Ladabaum U Am J Gastroenterol; 2013 Jan; 108(1):120-32. PubMed ID: 23247579 [TBL] [Abstract][Full Text] [Related]
10. Cost Effectiveness of Screening Individuals With Cystic Fibrosis for Colorectal Cancer. Gini A; Zauber AG; Cenin DR; Omidvari AH; Hempstead SE; Fink AK; Lowenfels AB; Lansdorp-Vogelaar I Gastroenterology; 2018 Feb; 154(3):556-567.e18. PubMed ID: 29102616 [TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness and National Effects of Initiating Colorectal Cancer Screening for Average-Risk Persons at Age 45 Years Instead of 50 Years. Ladabaum U; Mannalithara A; Meester RGS; Gupta S; Schoen RE Gastroenterology; 2019 Jul; 157(1):137-148. PubMed ID: 30930021 [TBL] [Abstract][Full Text] [Related]
12. The cost-effectiveness of non-invasive stool-based colorectal cancer screening offerings from age 45 for a commercial and medicare population. Ebner D; Kisiel J; Barnieh L; Sharma R; Smith NJ; Estes C; Vahdat V; Ozbay AB; Limburg P; Fendrick AM J Med Econ; 2023; 26(1):1219-1226. PubMed ID: 37752872 [TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness of Multitarget Stool DNA Testing vs Colonoscopy or Fecal Immunochemical Testing for Colorectal Cancer Screening in Alaska Native People. Redwood DG; Dinh TA; Kisiel JB; Borah BJ; Moriarty JP; Provost EM; Sacco FD; Tiesinga JJ; Ahlquist DA Mayo Clin Proc; 2021 May; 96(5):1203-1217. PubMed ID: 33840520 [TBL] [Abstract][Full Text] [Related]
14. Should colorectal cancer screening be considered in elderly persons without previous screening? A cost-effectiveness analysis. van Hees F; Habbema JD; Meester RG; Lansdorp-Vogelaar I; van Ballegooijen M; Zauber AG Ann Intern Med; 2014 Jun; 160(11):750-9. PubMed ID: 24887616 [TBL] [Abstract][Full Text] [Related]
15. Impact of assumptions on future costs, disutility and mortality in cost-effectiveness analysis; a model exploration. Omidvari AH; Lansdorp-Vogelaar I; de Koning HJ; Meester RGS PLoS One; 2021; 16(7):e0253893. PubMed ID: 34252090 [TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of patient navigation to increase adherence with screening colonoscopy among minority individuals. Ladabaum U; Mannalithara A; Jandorf L; Itzkowitz SH Cancer; 2015 Apr; 121(7):1088-97. PubMed ID: 25492455 [TBL] [Abstract][Full Text] [Related]
17. Comparative Effectiveness and Cost-Effectiveness of Colorectal Cancer Screening With Blood-Based Biomarkers (Liquid Biopsy) vs Fecal Tests or Colonoscopy. Ladabaum U; Mannalithara A; Weng Y; Schoen RE; Dominitz JA; Desai M; Lieberman D Gastroenterology; 2024 Jul; 167(2):378-391. PubMed ID: 38552670 [TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of colorectal cancer screening using colonoscopy, fecal immunochemical test, and risk score. Sekiguchi M; Igarashi A; Sakamoto T; Saito Y; Esaki M; Matsuda T J Gastroenterol Hepatol; 2020 Sep; 35(9):1555-1561. PubMed ID: 32167186 [TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of a patient navigation intervention to increase colonoscopy screening among low-income adults in New Hampshire. Rice K; Sharma K; Li C; Butterly L; Gersten J; DeGroff A Cancer; 2019 Feb; 125(4):601-609. PubMed ID: 30548480 [TBL] [Abstract][Full Text] [Related]
20. Clinical and Economic Impact of Tailoring Screening to Predicted Colorectal Cancer Risk: A Decision Analytic Modeling Study. Ladabaum U; Mannalithara A; Mitani A; Desai M Cancer Epidemiol Biomarkers Prev; 2020 Feb; 29(2):318-328. PubMed ID: 31796524 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]